Role of p53 gene polymorphism and bladder cancer predisposition in northern India

Cancer Biomarkers

Volumn 8, Issue 1, 2010, Pages 21-28

  Srivastava, Priyanka ^a   Jaiswal, Praveen K ^a   Singh, Vibha ^a   Mittal, Rama D ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Bacillus Calmette Gu rin; bladder cancer; haplotypes; p53; recurrence free survival

Indexed keywords

BCG VACCINE; GENOMIC DNA; PROTEIN P53;

ADULT; ALLELE; ARTICLE; BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; EXON; FEMALE; GENE INTERACTION; GENOTYPE; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INDIA; INTRON; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK REDUCTION; SMOKING;

BCG VACCINE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; IMMUNOTHERAPY; INDIA; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SMOKING; URINARY BLADDER NEOPLASMS;

MYCOBACTERIUM BOVIS BCG;

EID: 80052597972     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/DMA-2011-0816     Document Type: Article

References (23)

1. P. Hainaut and M. Hollstein, p53 and human cancer: the first ten thousand mutations, Adv Cancer Res 77 (2000), 81-137. (Pubitemid 29439303)
2. J.L. Prescott, J. Montie, T.W. Pugh, T. McHugh and R.W. Vel-tri, Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens, Cancer 91 (2001), 2127-2135. (Pubitemid 32476378)
3. E. Borkowska, A. Binka-Kowalska, M. Constantinou, A. Nawrocka, J. Matych and B. Kaluzewski, P53 mutations in urinary bladder cancer patients from Central Poland, J Appl Genet 48 (2007), 177-183. (Pubitemid 46743582)
4. A. Hartmann, G. Schlake, D. Zaak, E. Hungerhuber, A. Hof-stetter, F. Hofstaedter and R. Knuechel, Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder, Cancer Res 62 (2002), 809-818. (Pubitemid 34126958)
5. B. Vogelstein, D. Lane and A.J. Levine, Surfing the p53 network, Nature 408 (2000), 307-310.
6. M.S. Greenblatt, W.P. Bennett, M. Hollstein and C.C. Harris, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res 54 (1994), 4855-4878. (Pubitemid 24289415)
7. T. Soussi, S. Kato, P.P. Levy and C. Ishioka, Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations, Hum Mutat 25 (2005), 6-17. (Pubitemid 40075908)
8. Y. Kakudo, H. Shibata, K. Otsuka, S. Kato, and C. Ishioka, Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s, Cancer Res 65 (2005), 2108-2114. (Pubitemid 40490116)
9. S.F. Shariat, R. Ashfaq, A.I. Sagalowsky et al., Predictive value of cell cycle biomarkers in non-muscle invasive bladder transitional cell carcinoma, J Uro 177 (2007), 481-487. (Pubitemid 46054033)
10. M. Colombel, M. Soloway and H. Akaza, Epidemiology, staging, grading and risk stratification of bladder cancer, Eur Urol Suppl 7 (2008), 618-626.
11. S.A. Miller, D.D. Dykes and H.F. Polesky, A simple salting out procedure for extracting DNA from human nucleated cells, Nucleic Acids Res 16 (1988), 1215.
12. Z. Hu, C. Li, K. Chen, L.E. Wang, E.M. Sturgis, M.R. Spitz and Q. Wei, Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correlation Analysis, J Cancer Epidemiol 2008 (2008), 147905.
13. X. Wu, H. Zhao, C.I. Amos, S. Shete, N. Makan, WK. Hong, F.F. Kadlubar et al., p53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity, JNatl Cancer Inst 94 (2002), 681-690. (Pubitemid 34552489)
14. S. Wang-Gohrke, W Weikel, H. Risch, D. Vesprini, J. Abra-hamson, C. Lerman, A. Godwin et al., Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations, BrJ Cancer 81 (1999), 179-183. (Pubitemid 29415510)
15. B.L. Sprague, A. Trentham-Dietz, M. Garcia-Closas, PA. Newcomb, L. Titus-Ernstoff, J.M. Hampton, S.J. Chanock et al., Genetic variation in TP53 and risk of breast cancer in a population-based case control study, Carcinogenesis 28 (2007), 1680-1686. (Pubitemid 47289028)
16. S. Peller, A. Halevy, S. Slutzki, Y. Kopilova and V. Rotter, p53 mutations in matched primary and metastatic human tumors, Mol Carcinog 13 (1995), 166-172.
17. V.R. Katkoori, X. Jia, C. Shanmugam, W. Wan, S. Meleth, H Bumpers, WE. Grizzle et al., Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma, Clin Cancer Res 15 (2009), 2406-2416.
18. Z.Z. Zhu, A.Z. Wang, H.R. Jia, X.X. Jin, X.L. He, L.F. Hou and G. Zhu, Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population, Jpn J Clin Oncol 37 (2007), 385-390. (Pubitemid 47248959)
19. WD. Henner, A.J. Evans, K.M. Hough, E.L. Harris, B.A. Lowe and T.M. Beer, Association of codon 72 polymorphism of p53 with lower prostate cancer risk, Prostate 49 (2001), 263-266. (Pubitemid 33117001)
20. A. Storey, M. Thomas, A. Kalita, C. Harwood, D. Gardiol, F. Mantovani, J. Breuer et al., Role of a p53 polymorphism in the development of human papillomavirus-associated cancer, Nature 393 (1998), 229-234. (Pubitemid 28261713)
21. A. Själander, R. Birgander, G. Hallmans, S. Cajander, P. Lenner, L. Athlin, G. Beckman et al., p53 polymorphisms and haplotypes in breast cancer, Carcinogenesis 17 (1996), 1313-1316.
22. F Gemignani, V. Moreno, S. Landi, N. Moullan, A. Chabrier, S. Gutiérrez-Enŕiquez, J. Hall et al., A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA, Oncogene 23 (2004), 1954-1956. (Pubitemid 38445422)
23. T. Sun, X. Miao, X. Zhang, W Tan, P. Xiong and D. Lin, Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma, J Natl Cancer Inst 96 (2004), 1030-1036. (Pubitemid 39162646)